Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CBS Co. stock logo
CBS
CBS
$40.16
$35.02
$53.71
$15.28B1.213.65 million shs25.53 million shs
Elan Corporation, plc stock logo
ELN
Elan
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$0.86
+2.4%
$0.95
$0.51
$4.31
$7.55M-0.223.56 million shs84,936 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CBS Co. stock logo
CBS
CBS
0.00%0.00%0.00%0.00%0.00%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
+4.96%+22.83%-25.03%+83,969,900.00%+83,969,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CBS Co. stock logo
CBS
CBS
N/AN/AN/AN/AN/AN/AN/AN/A
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CBS Co. stock logo
CBS
CBS
N/AN/AN/AN/A
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CBS Co. stock logo
CBS
CBS
$14.51B0.00N/A6.84$7.52 per share0.00
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CBS Co. stock logo
CBS
CBS
$1.96B$5.197.860.000.7318.98%44.13%7.94%N/A
Elan Corporation, plc stock logo
ELN
Elan
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CBS Co. stock logo
CBS
CBS
$0.72N/AN/A13.87%N/A
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CBS Co. stock logo
CBS
CBS
2.04
1.52
1.05
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CBS Co. stock logo
CBS
CBS
76.99%
Elan Corporation, plc stock logo
ELN
Elan
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%

Insider Ownership

CompanyInsider Ownership
CBS Co. stock logo
CBS
CBS
0.56%
Elan Corporation, plc stock logo
ELN
Elan
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
3.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CBS Co. stock logo
CBS
CBS
12,770374.73 millionN/AOptionable
Elan Corporation, plc stock logo
ELN
Elan
N/AN/AN/ANot Optionable
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A8.79 million8.47 millionN/A

GWMO, CBS, ELN, VIC, and PBM Headlines

SourceHeadline
Psyence Biomedical (NASDAQ:PBM)  Shares Down 1.8% Psyence Biomedical (NASDAQ:PBM) Shares Down 1.8%
americanbankingnews.com - April 18 at 2:44 AM
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
finance.yahoo.com - April 17 at 12:49 PM
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
globenewswire.com - April 17 at 8:00 AM
Psyence Groups NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
globenewswire.com - April 16 at 11:01 AM
Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial
tmcnet.com - April 8 at 12:13 PM
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
globenewswire.com - April 8 at 8:00 AM
Psyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessPsyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
finanznachrichten.de - March 28 at 6:23 PM
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical BusinessPsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
globenewswire.com - March 26 at 11:06 AM
Psyence Biomedical Ltd PBMPsyence Biomedical Ltd PBM
morningstar.com - March 24 at 7:23 PM
PBM Psyence Biomedical Ltd.PBM Psyence Biomedical Ltd.
seekingalpha.com - March 22 at 8:02 PM
Psyence Biomedical Ltd (PBM)Psyence Biomedical Ltd (PBM)
uk.investing.com - March 21 at 4:24 PM
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
stockhouse.com - March 18 at 7:19 PM
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
globenewswire.com - March 18 at 4:05 PM
Psyence Biomedical faces Nasdaq delisting over market valuePsyence Biomedical faces Nasdaq delisting over market value
uk.investing.com - March 17 at 3:36 PM
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held SharesPsyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
globenewswire.com - March 15 at 4:30 PM
Psyence Groups NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb StudyPsyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
globenewswire.com - March 12 at 11:15 AM
Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future MilestonesPsyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
globenewswire.com - March 12 at 7:00 AM
Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In AustraliaPsyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
benzinga.com - March 11 at 7:54 PM
Why Is Psyence Biomedical (PBM) Stock Up 90% Today?Why Is Psyence Biomedical (PBM) Stock Up 90% Today?
investorplace.com - March 8 at 6:17 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

CBS logo

CBS

NYSE:CBS
CBS Corporation operates as a mass media company worldwide. The company operates in four segments: Entertainment, Cable Networks, Publishing, and Local Media. The Entertainment segment distributes a schedule of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and/or distributes programming, including series, specials, news, and public affairs; operates online content networks for information and entertainment; produces theatrical films; and digital streaming services. This segment also operates CBS Sports Network, a 24-hour cable program service that provides college sports and related content. The Cable Networks segment offers subscription program services, such as original series, theatrical feature films, documentaries, boxing and other sports-related programming, and special events, as well as a direct-to-consumer digital streaming subscription. This segment also operates Smithsonian Networks, which operates a channel featuring cultural, historical, scientific, and educational programs. The Publishing segment publishes and distributes adult and children's consumer books in printed, digital, and audio formats; develops special imprints and publishes titles based on the products of the company, as well as that of third parties; and distributes products for other publishers. This segment also delivers content; and promotes its products on its Websites, social media, and general Internet sites, as well as those related to individual titles. The Local Media segment owns 29 broadcast television stations; and operates local Websites, including content from its television stations. The company was founded in 1986 and is headquartered in New York, New York.
Elan logo

Elan

NYSE:ELN
Elan Corporation Ltd (Elan), formerly Elan Corporation, plc, is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP and other assets related to Tysabri. As of 31 December 2012, there were approximately 72,700
Psyence Biomedical logo

Psyence Biomedical

NASDAQ:PBM
Newcourt Acquisition Corp is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. Newcourt Acquisition Corp is based in Oakland, California.